NCT05761366 is a Phase 2 clinical trial of Al18F-PSMA-BCH PET/CT in Malignancy, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Who is sponsoring NCT05761366?

NCT05761366 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

What drugs are being tested in NCT05761366?

Interventions in NCT05761366: Al18F-PSMA-BCH PET/CT.

What condition does NCT05761366 study?

NCT05761366 studies Malignancy.

Is NCT05761366 still recruiting?

NCT05761366 is currently recruiting now. Last updated 27 December 2024.

Last reviewed 2024-12-27 · How we verify

NCT05761366

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Recruiting now Phase 2 Last updated 27 December 2024

What this trial tests

Phase 2 trial testing Al18F-PSMA-BCH PET/CT in Malignancy in 400 participants. Currently enrolling.

Timeline

13 October 2022

Primary endpoint
13 October 2025

13 October 2025

Quick facts

Lead sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	400
Start date	13 October 2022
Primary completion	13 October 2025
Estimated completion	13 October 2025
Sites	1 location across China

Drugs / interventions tested

Al18F-PSMA-BCH PET/CT — full drug profile →

Conditions studied

Malignancy — all drugs for Malignancy →

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

18 and older, any sex, with Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical value of [<sup>18</sup>F]AlF-Thretide PET/CT and early-time-point PET acquisition in the detection and staging of prostate cancer.
Cheng X, Hou G, Wang M, Zheng S, et al · · 2025 · cited 1× · PMID 40093904 · DOI 10.7150/thno.103667

Verify or expand the search:

Other recruiting trials for Malignancy

Currently open trials in the same condition.

NCT06999785 — Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperba · NA · recruiting
NCT06789601 — Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository · Phase 1, PHASE2 · recruiting
NCT04991922 — BostonGene-Integrated Genomic Registry (BIGR) · recruiting
NCT04656873 — Immuno-Oncology Database and Bioregistry · active not recruiting
NCT07338006 — Chest Wall Reconstruction Cohort · NA · recruiting

Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05761366 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Last refreshed: 27 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05761366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing